The proposed price per share, $81.50, if achieved, would yield approximately $358.6 million in gross proceeds for Onyx. From this sum would be deducted underwriting discounts, commissions, and other expenses related to the offering. Onyx may, however, reap more funds (as much as $53.8 million) from the offering if underwriters exercise all or part of a proposed 660,000-share overallotment offering.
Among other things, Onyx says that it will use the proceeds from this offering to fund its clinical development programs, research and development activities, and sales and marketing activities aimed at commercializing its Kyprolis multiple myeloma drug.
Shares of Onyx dropped 5% Wednesday, closing at $79.28.
Fool contributor Rich Smith has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.